Testing a new peanut allergy treatment (ENP-501)
Part of Immune system & allergy clinical trials.
This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 50 years old.
- You must have a doctor-confirmed history of peanut allergy (for the peanut-allergy groups).
- You must be willing to avoid peanuts completely during the study.
- You must be in generally good health, with no severe asthma or other serious lung problems.
- You cannot have had a life-threatening allergic reaction to peanuts that required a breathing tube or IV drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.
This trial tests a new immunotherapy called UKK-0018 to treat peanut allergies in adults. The goal is to help your body become less sensitive to peanuts over time.
This early-phase study tests VE416, a treatment meant to help reduce peanut allergy reactions by changing how the immune system responds. If you have documented peanut allergy, you may receive the study medicine and, for some people, take part in a supervised peanut “entry challenge.”
This trial studies whether an immune-supportive diet can improve gut health (gut permeability) in children with confirmed peanut or tree-nut allergy. If you join, the researchers will use allergy testing and gut-related diet approaches to see whether symptoms and gut measures change.
This Phase 2 study tests whether taking capsules made from donor gut microbes is safe and can reduce allergic reactions to peanuts. It involves peanut allergy testing and close follow-up with stool samples and check-ins.
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
Hear when a new Peanut Allergy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.